
|Articles|July 1, 2002
Modified steroid has 'potential' for treating subfoveal CNV in AMD
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Anecortave acetate (Alcon), a chemically modified steroid, acts in a unique way to suppress abnormal blood vessel growth in patients with subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SparingVision completes PRODYGY trial patient dosing with SPVN06
2
American College of Physicians Calls for An End of the Term 'Provider' in Policy Paper
3
Angiogenesis 2026: Continuous AI severity scoring could transform AMD monitoring
4
4DMT completes enrollment in 4FRONT-1, phase 3 trial of 4D-150 in AMD
5




























